Philips collaborates with leading institutes to bring its breakthrough spectral CT imaging into the interventional suite
November 24 2021 - 8:00AM
November 24, 2021
- Philips showcases world’s first spectral detector angio-CT
solution at RSNA 2021
- Solution combines breakthrough spectral detector CT imaging and
real-time fluoroscopy in a flexible environment where all
modalities are operated through Philips Image-Guided Therapy System
– Azurion with FlexArm
- Philips’ Spectral detector CT imaging in the interventional
suite brings valuable additional information in minimally-invasive
procedures for areas such as oncology, stroke, and trauma care
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
unveiled its vision for interventional medicine by bringing its
breakthrough spectral CT imaging technology into a hybrid Angio CT
suite. By combining the company’s unique Spectral CT 7500 system
and its Image-Guided Therapy System – Azurion with FlexArm in a
single interventional suite solution, Philips aims to give
interventionalists immediate table-side access to these two key
imaging modalities so they can perform procedures requiring both CT
and angio guidance in one room. For the development of this
integrated solution Philips is closely collaborating with leading
clinical institutes such as Mayo Clinic (Rochester, MN, U.S.) and
Baptist Health’s Miami Cardiac & Vascular Institute (Miami, FL,
U.S.). It is being presented at the 2021 Radiological Society of
North America Annual Meeting (Chicago, USA, November 28 – December
2).
The goal of combining the breakthrough, first of a kind Spectral
CT 7500 with the Azurion platform is to provide a seamless workflow
environment in which all the necessary imaging modalities - are
available directly at the patient table, fully controllable from
the table-side work spot. When not in use, each modality glides
smoothly away from the patient table into a parking position,
giving the interventional team unrestricted access to the patient.
Each system can work stand-alone if required. For
interventionalists, it enables seamless efficient workflows without
the need to move the patient from one imaging suite to another. For
patients, this means their physicians can leverage the strengths of
both systems during a single procedure.
Requiring just one scan to capture all the spectral information
required to differentiate and quantify different tissues, Philips’
always-on spectral CT technology enables improved detection,
delineation, and quantification of lesions, leading to
better-informed planning for minimally-invasive procedures and more
precise interventions. In oncology, spectral CT has also
demonstrated a higher sensitivity in detecting malignant findings
and has improved readings of incidental findings [1] [2].
“There has been a tremendous evolution in the image-guided
therapy environment,” said Dr. Barry T. Katzen, founder and chief
medical executive of Baptist’s Health’s Miami Cardiac &
Vascular Institute. “We are really excited about the merger and
integration of these technologies in that it might allow us to look
at the treatment of a number of diseases in very new and innovative
ways, potentially offering new treatment opportunities and
improving patient care. I am looking forward to investigating the
possibilities of this promising innovation.”
“With this innovation, we are taking a uniquely patient-centric
approach, aimed at bringing the latest interventional imaging
modalities to the patient table rather than moving the patient to
the individual modalities,” said Karim Boussebaa, General Manager
of Image Guided Therapy Systems at Philips. “We are excited to be
co-creating the future of image guided therapy with leading
clinical partners by combining the best of our award-winning
modalities into a single suite.”
Follow @PhilipsLiveFrom for updates throughout RSNA 2021, and
join Philips at RSNA 2021 where the company will spotlight its
latest advanced technology driving connected workflows and smart
connected imaging systems.
[1] Analysis by Aarhus University Hospital Aarhus, Denmark.
Results from case studies are not predictive of results in other
cases. Results in other cases may vary. [2] Analysis by University
Hospital Cleveland, USA. Results from case studies are not
predictive of results in other cases. Results in other cases may
vary.
For further information, please contact:
Joost MalthaPhilips Global Press OfficeTel: +31 610 558
116Email: joost.maltha@philips.com
Kathy O’ReillyPhilips Global Press OfficeTel. + 1
978-221-8919E-mail kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2023 to Apr 2024